Trial Profile

A phase 2 clinical trial of ILYX-002 in immune-driven dry eye disease (DED)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ILYX 002 (Primary)
Indications Dry eyes
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use

Most Recent Events

09 Oct 2025 According to the Iolyx Therapeutics Media Release, company announced that the company will present clinical data from its Phase 2 clinical trial of ILYX-002 in patients with dry eye disease (DED) associated with autoimmune or systemic inflammatory disease in an oral session at Eyecelerator @ American Academy of Ophthalmology (AAO) 2025 and in an on-demand poster during the AAO Annual Meeting, being held October 16, 2025 and from October 18 - 20, respectively, in Orlando, Florida.
27 May 2025 Results published in the Iolyx Therapeutics Media Release
28 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com